@RealDrJaneRuby
Mammograms CAUSE CANCER
Breast tissue is comprised of complex, delicate structures like ducts, mammary glands, tubules. Crushing all those structures down flat, and then radiating through condensed tissues begins the mechanical and chemical damage. 

U.S. Medical System Is A Fraud

Mammograms CAUSE CANCER

Breast tissue is comprised of complex, delicate structures like ducts, mammary glands, tubules. Crushing all those structures down flat, and then radiating through condensed tissues begins the mechanical and chemical damage.

U.S. Medical System Is A… pic.twitter.com/FzM5PIsp5c

— DR JANE RUBY™️ (@RealDrJaneRuby) November 25, 2024

Mammography screening is harmful and should be abandoned

Mammography screening remains a controversial topic. Systematic reviews conducted by organizations without conflicts of interest, such as the Nordic Cochrane Centre, the US and Canadian Task Forces, the Independent UK Panel, and the Swiss Medical Board, have identified significant issues with the randomized trials used to evaluate mammography screening. As a result, determining the true effect of mammography screening is challenging.

One major concern is the age of the trials. Most of these studies began between 1963 and 1982, during a time when adjuvant therapies like anti-hormonal treatment and chemotherapy were not widely used. The introduction of effective drugs has significantly reduced the potential benefits of screening. For some women, improved therapies have extended their lives to the point where they may die from other causes, such as heart disease, before their breast cancer becomes life-threatening. Additionally, since the effectiveness of adjuvant therapy is largely independent of nodal status and other tumor characteristics, it can be beneficial regardless of whether the cancer is detected early.

Another critical issue is the potential bias in assessing the cause of death, which tends to favor screening. A meta-regression analysis of the trials revealed that even when screening effectiveness was zero (i.e., the rate of node-positive cancers was the same in both screened and control groups), there was still a predicted 16% reduction in breast cancer mortality. This suggests the presence of bias in the assessment of cause of death and the number of advanced-stage cancers, both of which appear to be skewed in favor of screening.

The historical context of these trials is important to consider, but their relevance to current medical practices is limited. When screening was introduced about 25 years ago, the average tumor size in the screened groups was 16 mm, compared to 21 mm in the control groups. This small difference in size, representing just one additional cell division, raises questions about the plausibility of screening having a significant impact on breast cancer mortality.

Conclusions

In conclusion, the controversy surrounding mammography screening persists due to the limitations of the original trials, potential biases in data interpretation, and the evolving landscape of breast cancer treatment. These factors make it difficult to definitively determine the true effectiveness of mammography screening in reducing breast cancer mortality.

References

• 1.Gøtzsche PC, Jørgensen KJ. Screening for breast cancer with mammography. Cochrane Database Syst Rev 2013; 6: CD001877–CD001877. (first published in 2001). [DOI] [PMC free article] [PubMed] [Google Scholar]
• 2.Humphrey LL, Helfand M, Chan BK, Woolf SH. Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 137: 347–360. [DOI] [PubMed] [Google Scholar]
• 3.Canadian Task Force on Preventive Health Care, Tonelli M, Connor Gorber S, Joffres M, Dickinson J, Singh H, Lewin G, et al. Recommendations on screening for breast cancer in average-risk women aged 40–74 years. CMAJ 2011; 183: 1991–2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
• 4.Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet 2012; 380: 1778–1786. [DOI] [PubMed] [Google Scholar]
• 5.Biller-Andorno N, Jüni P. Abolishing mammography screening programs? A view from the Swiss Medical Board. N Engl J Med 2014; 370: 1965–1967. [DOI] [PubMed] [Google Scholar]
• 6.Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687–1717. [DOI] [PubMed] [Google Scholar]
• 7.Gøtzsche PC. Relation between breast cancer mortality and screening effectiveness: systematic review of the mammography trials. Dan Med Bull 2011; 58: A4246–A4246. [PubMed] [Google Scholar]
• 8.Gøtzsche PC. Mammography screening: truth, lies and controversy, London: Radcliffe, 2012.[DOI] [PubMed] [Google Scholar]
• 9.Gøtzsche PC, Jørgensen KJ, Zahl PH, Mæhlen J. Why mammography screening has not lived up to expectations from the randomised trials. Cancer Causes Control 2012; 23: 15–21. [DOI] [PubMed] [Google Scholar]
• 10.Autier P, Boniol M, Middleton R, Doré JF, Héry C, Zheng T, et al. Advanced breast cancer incidence following population-based mammographic screening. Ann Oncol 2011; 22: 1726–1735.[DOI] [PMC free article] [PubMed] [Google Scholar]
• 11.Kalager M, Adami HO, Bretthauer M, Tamimi RM. Overdiagnosis of invasive breast cancer due to mammography screening: results from the Norwegian screening program. Ann Intern Med 2012; 156: 491–499. [DOI] [PubMed] [Google Scholar]
• 12.Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med 2012; 367: 1998–2005. [DOI] [PubMed] [Google Scholar]
• 13.Jørgensen KJ, Gøtzsche PC. Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. BMJ 2009; 339: b2587–b2587. [DOI] [PMC free article] [PubMed] [Google Scholar]
• 14.Jørgensen KJ, Zahl PH, Gøtzsche PC. Breast cancer mortality in organised mammography screening in Denmark: comparative study. BMJ 2010; 340: c1241–c1241. [DOI] [PMC free article] [PubMed] [Google Scholar]
• 15.Kalager M, Zelen M, Langmark F, Adami HO. Effect of screening mammography on breast-cancer mortality in Norway. N Engl J Med 2010; 363: 1203–1210. [DOI] [PubMed] [Google Scholar]
• 16.Autier P, Boniol M, Gavin A, Vatten LJ. Breast cancer mortality in neighbouring European countries with different levels of screening but similar access to treatment: trend analysis of WHO mortality database. BMJ 2011; 343: d4411–d4411. [DOI] [PMC free article] [PubMed] [Google Scholar]
• 17.Bleyer A. US breast cancer mortality is consistent with European data. BMJ 2011; 343: d5630–d5630. [DOI] [PubMed] [Google Scholar]
• 18.Jørgensen KJ, Zahl PH, Gøtzsche PC. Overdiagnosis in organised mammography screening in Denmark: a comparative study. BMC Womens Health 2009; 9: 36–36. [DOI] [PMC free article] [PubMed] [Google Scholar]
• 19.Zahl PH, Jørgensen KJ, Gøtzsche PC. Overestimated lead times in cancer screening has led to substantial underestimation of overdiagnosis. Br J Cancer 2013; 109: 2014–2019. [DOI] [PMC free article] [PubMed] [Google Scholar]
• 20.Pharoah PD, Sewell B, Fitzsimmons D, Bennett HS, Pashayan N. Cost effectiveness of the NHS breast screening programme: life table model. BMJ 2013; 346: f2618–f2618. [DOI] [PMC free article] [PubMed] [Google Scholar]
• 21.Baum M. Harms from breast cancer screening outweigh benefits if death caused by treatment is included. BMJ 2013; 346: f385–f385. [DOI] [PubMed] [Google Scholar]
• 22.Brodersen J, Siersma VD. Long-term psychosocial consequences of false-positive screening mammography. Ann Fam Med 2013; 11: 106–115. [DOI] [PMC free article] [PubMed] [Google Scholar]
• 23.Raftery J, Chorozoglou M. Possible net harms of breast cancer screening: updated modelling of Forrest report. BMJ 2011; 343: d7627–d7627. [DOI] [PMC free article] [PubMed] [Google Scholar]
• 24.Swiss Medical Board. Systematisches Mammographie-Screening. See www.medicalboard.ch/fileadmin/docs/public/mb/Fachberichte/2013-12-15_Bericht_Mammographie_Final_Kurzfassung_e.pdf (last checked 15 December 2013).
• 25.Jørgensen KJ, Keen JD, Gøtzsche PC. Is mammographic screening justifiable considering its substantial overdiagnosis rate and minor effect on mortality? Radiology 2011; 260: 621–627. [DOI] [PubMed] [Google Scholar]